Live feed07:00:00·11dPRReleasevia QuantisnowCastle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMSByQuantisnow·Wall Street's wire, on your screen.CSTL· Castle Biosciences Inc.Health Care
